Lipodystrophy during pegvisomant therapy: a case report and review of the literature

Buyuktas, D; Celik, O; Kantarci, F; Kadioglu, P

doi:10.1590/S1807-59322010000900018

LETTER THE TO EDITOR

^IDivision of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey

^IIDivision of Radiology, Cerrahpasa Medical School, University of 0stanbul, 0stanbul, Turkey. Email: kadioglup@yahoo.com Tel.: 90-216-462 31 14 / 90-532-404 10 40

INTRODUCTION

Acromegaly is a serious, chronic endocrine disorder characterized by exaggerated growth hormone (GH) secretion and increased levels of insulin-like growth factor-1 (IGF-1). Treatment modalities include somatostatin analogues and pegvisomant and/or radiotherapy following pituitary tumor resection.¹ Pegvisomant is a pegylated analogue of human GH and functions as a GH receptor antagonist. Pegvisomant acts in the periphery and significantly decreases serum IGF-1 levels.² Various studies have shown that pegvisomant is safe and well-tolerated and is an effective therapy for acromegaly patients. Possible adverse effects of pegvisomant treatment include self-limited erthematous injection-site reactions, mild liver toxicity, influenza-like syndrome and headache.³ Here, we describe an acromegalic patient who developed lipohypertrophy following initiation of pegvisomant therapy.

CASE REPORT

A 61-year-old female patient was diagnosed with acromegaly eight years ago. The diagnosis of acromegaly was confirmed by elevated serum IGF-1 levels accompanied by failure of GH suppression following a 75 g glucose load. The patient displayed a 22x17x16 mm pituitary adenoma, which was operated transsphenoidally two months after diagnosis. After surgery, the patient was treated with long-acting octreotide LAR for persistent symptoms. After 14 months of octreotide therapy, 0.5 mg cabergoline administered 3 days a week was added to the treatment regimen to address unremitting symptoms. The patient underwent a gamma-knife procedure three years after the initial surgery to treat the residual disorder, which was identified by persistently high levels of IGF-I and magnetic resonance imaging (MRI). At the 4^th year of follow up, the patient displayed an IGF-I level of 485 ng/ml. At this point (December 2009), carbegoline treatment was discontinued and the patient was given subcutaneous injections of 10 mg pegvisomant per day. The patient was advised to alternate the injection areas around the arms, thighs and the abdominal wall. After two months of treatment, the patient found soft, painful swellings on her arms, thighs and the abdominal wall. Clinical examination found a clearly visible thickening of the tissues in these areas (Figure 1). No significant increase was detected in serum IGF-1 levels, indicating that the treatment was effective. Ultrasonography revealed a subcutaneous fat hypertrophy in the extremities. MRI of the left arm confirmed lipomatous hypertrophy at the injection site (Figure 2).

The accuracy of the injection sites and the drug applications were controlled by a dedicated nurse (Somavert education service). The patient was dissatisfied with the lipohypertrophy at the sites of injection, and pegvisomant therapy was therefore discontinued.

DISCUSSION

Somatostatin analogues and pegvisomant are frequently used in the treatment of acromegaly. Pegvisomant is a pegylated analogue of human GH that blocks hepatic production of IGF-1. The adverse effects of pegvisomant therapy include self-limited erythematous injection-site reactions, mild liver toxicity, influenza-like syndrome, headache, asthenia, diarrhea, arthralgia and hypercholesterolemia.³

Lipodystrophy is a disease of the adipose tissue. It can be localized and acquired by administration of particular drugs. If the adipose changes are related to depressed areas of skin, the disease is called lipoatrophy. Lipohypertrophy is an enlargement of fat tissue caused by subcutaneous deposition of adipose and is associated with parenteral drug administration. The pathogenesis of lipohypertrophy is unclear. It is known that growth hormone and IGF-1 both display lipolytic activity. Blockage of growth hormone action through pegvisomant therapy can affect adipose size and increase local adiposity.^4-7 Immunologic factors can also contribute to lipodystrophy. An inflammatory reaction to substitutions of pegvisomant can often cause this disorder.⁸ However, a biopsy of a pegvisomant-induced lipohypertrophy from an acromegalic patient showed normal-appearing mature adipocytes with no fat necrosis and no inflammatory cells. Additionally, the biopsy showed no anti-pegvisomant antibodies.⁷

To our knowledge, the literature contains 4 reports describing 11 patients who developed lipodystrophy during pegvisomant therapy^5-8 (Table 1). These reports describe lipohypertrophy in 10 patients and lipoatrophy in 1 patient. Maffei et al. have reported one male and one female patient who suffered from lipohypertrophy on the abdominal wall, confirmed by ultrasonography and MRI, following 1 month of pegvisomant therapy. These patients were advised to avoid abdominal injections and alternate the injection sites.⁵ Salvatore et al. reported pegvisomant-induced lipoatrophy.⁶ Marazuela et al. described lipohypertrophy on the left arm of a female patient caused by pegvisomant therapy. This lipohypertrophy resolved once injections at the same site were ceased.⁷ Bonert et al. identified seven different cases of lipohypertrophy induced by pegvisomant therapy; two of the patients began rotating the injection site, and four patients discontinued pegvisomant therapy.⁸

Thumbnail

It is worth noting that 9 of the 11 patients described in the literature were female. Thus, pegvisomant-induced lipohypertrophy can be referred to as a gender-specific response. In most cases, lipohypertrophy was reversed after the injection site was rotated or treatment was discontinued. It is unknown whether the development of lipohypertrophy is associated with the dose or frequency of injection.^5,7,8 In our patient, pegvisomant therapy was administered together with a low dose of octreotide LAR. The treatment effectively normalized IGF-1 levels, but pegvisomant treatment was stopped due to discomfort caused by lipohypertrophy.

In conclusion, pegvisomant injection appears to have induced lipohypertrophy in our patient following two months of therapy. We recommend injection site rotation to different parts of the body, which should prevent the development of lipohypertrophy. Physicians should be aware of this complication and carefully monitor patients under pegvisomant treatment.

1. Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Pituitary tumours:acromegaly. Best Practise & Research Clinical Endocrinology & Metabolism. 2009;23:555-74, doi: 10.1016/j.beem.2009.05.010.
2. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrin Reviews. 2002; 23: 623-46, doi: 10.1210/er.2001-0022.
3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan Al,Katznelson L, et al. Lon-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-9, doi: 10.1016/S0140-6736(01)06844-1.
4. Mersebach H, Feldt-Ramussen UF .Localized lipohypertrophy during growth hormone therapy.Ugeskr Laeger. 2002;164:1930-2.
5. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Annals of Internal Medicine. 2006;145:310-2.
6. Salvatore C, Giovanni R, Vittorio C, Claudia S, Patrizia CS. Subcutaneous lipoatrophy induced by long-term pegvisomant administration. Clinical Endocrinology (Oxf). 2009;70: 655-6, doi: 10.1111/j.1365-2265.2008.03400.x.
7. Marazuela M, Dauden E, Ocon E, Moure D, Nattero L. Pegvisomant induced lipohypertrophy: report of a case with histopathology. Annals of Internal Medicine. 2007;147:741-3.
8. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. Journal of Clinical Endocrinology & Metabolism. 2008;93:3515-8, doi: 10.1210/jc.2008-0833.